Thanks, operator, . on earnings joined today's for and call by the our our Officer. call first Matt quarter Financial I'm everyone, welcome, XXXX. Hill, to Chief
brief and year. some our the operational you today's discussion team to me of has a with of this with call. of performance our begin Let first revenue made progress, of a outline important areas quarter I'll provide date
our and Matt earnings then reaffirmed guidance release today. financial our we which review in will XXXX, for quarterly results
I'll prepared questions. with discussion remarks a call XXXX outlook open priorities our for of our and before for then we brief conclude the
increased revenue get The revenue revenue a with let's partially of In driven sales by $XX.X to review was total growth Now of first year-over-year the offset decrease sales $X.X growth quarter, by our decreased products, our to started XX% year-over-year was total XX% results. million. Advanced Energy This in in which products, our which to declined XX% $X.X million. year-over-year of million. OEM
our a our more Energy in segment. to discussion of performance Turning detailed Advanced
in our outlined with consistent largely most were expectations results Energy Advanced quarter recent call earnings March. first in late Our our
to surgery purchasing continued in we the softness reminder, have market been similar for had mid-XXXX. capital cosmetic other in since industry our As companies facing expected equipment what a
the dynamics with the quarter during -- observed these expectations. remain consistent first We
high investments broader concerns interest macroeconomic the financing customers capital uncertainty, to and Specifically, in prospective environment about delaying team our with along continued new rates. see equipment mentioning
With driven the Energy the decrease predominantly was for year-over-year. which year-over-year our expectations Advanced this backdrop, slower performance of range in sales of by XX% segment generators quarter. as was This nearly with consistent during quarter sales a first the decreased
basis, was modestly our Global sales on range year-over-year of our within pieces this the quarter well. decline hand expectations decreased a but for of as
geographic a sales the Advanced From in by largely U.S. sales the year-over-year standpoint, decrease Energy in slower was driven
Given bring them to working cosmetic continued on customers surgery U.S. our practice. team surgeon with benefits the challenges in to market, understand their direct help sales remained has prospective can Renuvion the the that focused
return financing period investment potential on address explore front. payback its and and help different any appreciate on I options concerns to this
customer backdrop. an in new adoption has challenging environment pleased the the and both quarter their during current amidst I battle a performance uphill and Driving am efforts their remained market with
region, distributors U.S. notably our by most and to East sales both while saw Internationally, by Middle APAC. Europe, and pockets in vary we of strength Africa country regions, multiple and
experiencing. All reflect been our in QX we in line our Advanced to for Energy market and continue and with the industry others environment were in the sales expectations difficult all, have
efficiency controlling to headwinds. to minimize ways key on organization evaluate we organization our focused costs remain expenses. our we navigate continue these we and is Importantly, Cash across our as our for priority a
help improvement challenging in our our of market in year-over-year. pleased provided the offset business. reduction approximately on expenses were impact $XXX,XXX quarter environment We This significant the in the us operating X% the first or to of savings
operational Turning of to highlights. recent our a discussion
regulatory enhanced evidence, our in portfolio the which of and XXXX, of team products As Renuvion adoption provided focused clearances. is we leveraging utilization a us by driving important clinical reminder, progress part year, and technology made in our on last an
additional and micro XXX(k) with papers, clearances new Apyx importantly, X X published portfolio products clinical One XX and Specifically, our a Renuvion specific clinical we for over indications. generator entered most XXXX of handpiece
As following tissue for tissues of body technology for subcutaneous the a use subcutaneous including soft contouring in aesthetic new us is these needed, coagulating Renuvion contraction clearances used enable when soft liposuction tissue. our market and to reminder, to be
the after device liposuction use that Renuvion device the is contracting FDA only for tissue. cleared now cleared is for only subcutaneous and
According to Society the estimated procedure survey the performed global the Surgery Plastic XXXX. report of X.X International with liposuction commonly cosmetic in be the surgical an procedures from continued to million latest in Aesthetic most world
typically and aesthetic to be procedures, laxity body multistage treatments, skin fat will for important involve specific liposuction. contouring and that an long-term transfer We procedure believe target of demand deposits continue fat driver
soft procedures in given Renuvion these achieve integral safely, results. to an effectively impressive and to its contraction lasting ability role tissue has play deliver and
this all to efforts drive mind, new awareness offering. about first during our of quarter continued our potential educate their enhanced the With and Renuvion in customers team
I within team with their them benefits, offering. Renuvion's walk earlier, the existing technology position is As mentioned ROI surgeons to both their discuss and staff engaging to ways our of awareness this and drive its through
in educate new we supplementing featuring participated trade medical this X to of potential presentations with and part also shows, engage customers. technology and podium programming As initiative, additional surgeon XX our meetings
successful hosted physician providing users. directly customers programs some XX and these attended team physician surgeon the mentor also who prospective from events cases to learn Our X during quarter, of our observe the most
we potential Renuvion users, the our unique on existing them to to OUS new and of on addition helping both technology. surgeon continue capitalize support better In and distribution our benefits partners focus educate customers, our
and engage based our able during part and marketing As bring we countries the and learn we which quarter, hosted them distributed personnel our different will were provided first sales which their personnel activities and global countries. in customers, regions to in key opportunity believe The we cover. meeting over direct of benefit XX the from meeting, in sales to with they an
third by Vegas, XX, clinicians -- respect User attended customers our was With Summit in XX our countries. XXX surgeon existing Las Renuvion to on April we which over hosted from and
our XX Summit in key technology. featured opinion to research, enhance our from leaders from experience applied presentations, User patient outcomes which clinical be their of from technology enabling can ways findings of discuss hear Our as and with insights users a they the latest day our to
their users new to ideas own our to apply provided many with of This practices.
of this on available our all customers. of content now All demand is for
personal using event personal passion surgeons underscored they're what to with patients. at technology. stems they own the Renuvion their the experience latest for from terms me their have they My of and interactions this users in for the see difference providing
initiative. From a patient advertising marketing and develop enhance direct-to-consumer standpoint, we continue to also our
in Following pleased the reorganization leadership have DTC in team with new last campaigns experience of cosmetic are surgery advertising expertise quarter, marketing we market. prior place to and the significant senior in our
strategic to and are campaigns engaged to including our partner recently content. a DTC advertising create marketing new team initiatives with Our firm test new collaborating and whom on
We on program look to more our of forward regulatory clearances. to fully capitalize establishing new benefits a best-in-class the
raise efforts awareness, clinical evidence demonstrating the and our and the continue educate to our expand customers, Renuvion. addition support of we efficacy market existing to leverage safety In portfolio of to the and
In January, the we pleased for of of contracting the Journal subcutaneous soft a Renuvion the liposuction. were Forum, following in publication which tissue to peer-reviewed evaluated article Surgery safety see Open Aesthetic
the Renuvion and summarized a article subcutaneous data liposuction The patients tissue XXX of the conducted which treated Shridharani analysis on were an who from by soft following X,XXX of the body. with contraction for team, results total of areas real-world included of Dr.
published involve rates liposuction compared that sourced these adverse liposuction from the which studies. previous review procedures the safety they systematic for for evaluated event alone, to and them They of only rates procedures
conclusions X drew from authors analysis. The the important
First, use the risk no following they the found Renuvion use increased demonstrated new liposuction compared liposuction of or alone. to of
not liposuction subcutaneous they did tissue Renuvion of Second, differ significantly associated area. for with risks contraction soft the found following the by body use
of profile the is important community compelling excellent public. technology were now This we that clinical well as to represents analysis demonstrating safety pleased additional accessible the our medical the and widely broader evidence it as
Renuvion Scientific compared pleased a to Meeting Michael Dr. discussing clinical were we in study Annual retrospective competing February, use see results technology. presentation the the to a that ACS used the by commonly of a Kluska of At
the were was patients and Roughly half study the Dr. several over patients. and liposuction safety other technology. continuous with conducted series The and Renuvion procedure these collected of evaluated colleagues of XXX and half following who treated by with from treated a were demographic, data competing Kluska
found patient for difference researchers The events of each adverse number statistically significant in a the group.
scarring fewer comparison treated technology. the hypertrophic Renuvion to group significantly group seroma Specifically, competing hematoma, had treated in the with the with burns, and
of to available. published alternative directly an This to as evidence We addition for this devices safety compared and represents study made body it study hope our clinical commonly treatment. full see demonstrates important results when used Renuvion's profile compelling to its
our In Medical made on as XXXX, existing customers important operational in market clinical our for and to supporting and challenging improves. is positioning the focused backdrop, success evidence, our continuing portfolio capitalizing environment a utilization amidst while team driving of expand summary, adoption by Apyx future on progress
via announcement of to more of I would Matt, discuss the I morning. take release our press call minute After retiring this of important Chairman service Medical, like Before Directors. to is made and years XX an Board a over Makrides today turn as also Andrew to we Apyx than
would an the half and since of a contributor Bovie company's Apyx success Medical predecessor It the say nearly to understatement been an Andrew be that to has century Medical instrumental its founding ago.
for of has also the years serving its as Board -- Andrew company's time, XX for as member more since XX of served of operations of a he over as We strategy executive Chairman XXXX. Chief guided than of company's cofounders Officer Executive during has the the the much One company, and the and the team, years. President
an to him has and XXXX. to Andrew vision, to Medical as in the and and him of retirement. me since today best joined would members, Director Apyx thank shareholders, fellow CEO for to very colleagues I On in resource the and his opportunity like behalf strategic invaluable been wish the take guidance Board I dedication company my
has strategic to the Stavros been investor medical is device to to Vizirgianakis, like an Chairman. adviser our industry. I welcome would and who and serve Director Stavros companies new appointed in
of a medical leading includes companies in device career of Board the impressive space member the public as and as member private leadership team. His and a experience a senior significant
known Misonix was CEO medical perhaps from of acquired XXXX President this of held new as leadership by XXXX. and Bioventus in role company, a traded terms widely the the publicly Stavros experience, he former In is company until past most device
Xtant Ascendis also Medical Stavros' device publicly Corporation Board became part experience current traded Innovations, of at largest Theragenetics one Tally medical Africa's cofounded recent the Surgical Stavros Health and privately which Holdings. distributors, of Limited. owned positions Surgical, includes later
He next Medical and leveraging qualified to experience growth on and and is our Apyx insight suited forward look well going guide strategic creation. vision embark as we the of forward, we both and stage well his to of value
I we our to to sales with goal working growth improve look of value. explore increasing opportunities and the additional shareholder profitability, together forward as
financial reaffirmed of XXXX, first release. guidance financial with quarter will in we review Matt now which detail today's our results along our more in
